Retrophin Inc. Cmn (RTRX) 18.17 $RTRX Gilead's (GILD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Retrophin Inc. Cmn (RTRX) 18.17 $RTRX

Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:08AM CDT
Gilead Sciences' (GILD) once-daily single tablet regimen Odefsey gained EU approval for the treatment of HIV-1 infection in certain patients.
JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24)

Retrophin (RTRX) RE-024 Positive in Physician-Initiated Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:54AM CDT
Retrophin (RTRX) announced new data from a physician-initiated study on RE-024 for the treatment of pantothenate kinase-associated neurodegeneration (PKAN).
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), ORPN: 1.62 (-0.10)

Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.61 (-0.23), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), NYMX: 3.35 (-0.25)

Retrophin Announces New Data from Physician-Initiated Treatment with RE-024 at the 20th International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Thu Jun 23, 5:00AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced new data from physician-initiated treatment with RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic condition characterized by a host of progressively debilitating movement disorders. Key findings suggest RE-024 was safe and well tolerated in two adults with PKAN who experienced clinically meaningful improvements, followed by stabilization of disease progression over 47 weeks of treatment.
RTRX: 18.17 (+0.24)

Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.90 (-0.03), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), CELG: 114.69 (+2.50)

GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 96.11 (+1.79), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)

Inovio Stock Up, Zika Vaccine Gets Nod for Phase I Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 3:51PM CDT
Inovio Pharmaceuticals (INO) and GeneOne Life Science will begin the first Zika vaccine study in human volunteers; Inovio's stock gains.
INO: 10.42 (+0.54), ANIP: 61.06 (+0.46), XON: 27.38 (+2.05), RTRX: 18.17 (+0.24)

Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.99 (-0.08), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 80.46 (+0.99), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)

Auris (EARS) Begins Phase III Study for Sudden Deafness
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:31AM CDT
Auris Medical (EARS) has started patient enrollment in a second pivotal phase III study (ASSENT) on AM-111 for the treatment of sudden deafness.
EARS: 4.14 (+0.13), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)

Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:18PM CDT
Kura Oncology (KURA) announced the dosing of the first patient in a phase II study on tipifarnib for the treatment of lower risk myelodysplastic syndromes.
JNJ: 125.40 (+0.17), RTRX: 18.17 (+0.24), KURA: 4.31 (+0.20), BMY: 76.19 (+1.38)

7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.36 (unch), RTRX: 18.17 (+0.24), AVEO: 0.99 (-0.01), SNSS: 0.70 (+0.05), LGND: 138.53 (+3.65), BIND: 0.78 (-0.09), ACOR: 25.13 (-0.15)

Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:30AM CDT
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
GNRT: 5.11 (-0.21), FB: 124.31 (+0.37), RTRX: 18.17 (+0.24), QVCA: 26.55 (-0.26), DY: 93.78 (-0.27)

5 Profitable Stocks for Enhancing Your Portfolio Returns
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:18AM CDT
Among the profitability ratios, we have used net income ratio to determine a company's profitability position.
GNRT: 5.11 (-0.21), FB: 124.31 (+0.37), RTRX: 18.17 (+0.24), QVCA: 26.55 (-0.26), DY: 93.78 (-0.27)

Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), RVNC: 13.25 (-0.24), BMY: 76.19 (+1.38)

Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), AGIO: 45.69 (+0.46), BMY: 76.19 (+1.38)

Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 125.40 (+0.17), RTRX: 18.17 (+0.24), GSK: 45.25 (+0.18), BMY: 76.19 (+1.38)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.38 (+0.03), RTRX: 18.17 (+0.24), VVUS: 1.05 (-0.02), ARNA: 1.68 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 49

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 0

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 203

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
Blueprint Strengthens Team with New Capital Markets Director

Updated Category News Views 114

Blueprint Bolsters Its Ranks Hiring Caitlin Novak as Managing Director marks a pivotal step for Blueprint Healthcare Real Estate Advisors. They aren't just swapping pawns; they're making a statement, beefing up their capital markets strategy with a heavy hitter seasoned in steering around fiscal pitfalls. Novak isn’t some rookie wet behind the ears—she's clocked more...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 173

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 269

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 40

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
Wall Street Gains Hold Amid Volatility Drop

Updated Category News Views 61

A Week of Gains and Regulatory Moves Right out of the gate, it’s been a decent stretch for Wall Street. Weekly gains kept the party going, even as traders navigated the usual hurdles. Stocks finished the week with a solid performance—all the heavy hitters like Dow, S&P 500, Nasdaq, and Russell 2000 ended on a high note, waltzing uphill past where many imagined...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 77

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
e News Articles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles